Exact Sciences Closes $8.2-Million Private Placement, Enters Into Licensing and Collaboration Agreement

Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into a collaboration and license agreement with Mayo Clinic. Exact also announced that it has closed an $8.2-million private placement of 4.3 million shares of its common stock.

The collaborative relationship with Mayo Clinic is focused on developing patient-friendly diagnostics that reduce deaths from colorectal cancer. According to projections by the American Cancer Society there will be 146,970 new cases of colorectal cancer and 49,200 deaths attributable to the disease in 2009 in the United States. It is the second most common cause of cancer-related death following lung cancer.

Under the license agreement, Exact has secured exclusive rights to intellectual property developed by David Ahlquist, M.D., Mayo Clinic.

MedMira's HIV/Hepatitis C Rapid Test Selected by Centers for Disease Control and Prevention (CDC) for Collaborative Evaluation Program

MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that the Centers for Disease Control and Prevention (CDC) in the United States has selected the Company's Multiplo HIV/Hepatitis C (HCV) Rapid Test to be a part of a program entitled "Opportunity to Collaborate in the Evaluation of Rapid Diagnostic Tests for HIV and HCV".

This program of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) at the Centers for Disease Control and Prevention (CDC) of the Department of Health and Human Services (DHHS) will see evaluations done in laboratories and in the field to determine the viability of rapid tests for use in screening and/or diagnosis of HIV and HCV in the United States.

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

MicroRNA-based Molecular Diagnostics to Mark Prometheus' Entry into Oncology Market; Rosetta to Receive Milestones and Research and Development Funding plus Future Royalties

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd. (Nasdaq: ROSG), an innovative molecular diagnostic company, today announced the execution of a license and collaboration agreement under which Rosetta shall grant Prometheus U.S. rights to three recently introduced, microRNA-based cancer diagnostic tests: miRview(TM) mets, miRview(TM) squamous and miRview(TM) meso.

VCA Antech, Inc. Reports Fourth Quarter 2008 Results and Provides Financial Guidance for 2009

VCA Antech, Inc. (NASDAQ: WOOF), a leading animal healthcare company in the United States, today reported financial results for the quarter ended December 31, 2008, as follows: revenue increased 6.7% to a fourth quarter record of $303.2 million; gross profit increased 6.6% to $73.9 million; operating income increased 6.5% to $50.9 million; net income increased 4.3% to $25.7 million; and diluted earnings per share increased 3.4% to $0.30. Each fourth quarter of 2008 and 2007 included a benefit of $3.3 million and $3.5 million, respectively related to a decline in our estimated workers' compensation liability for previous years' policy periods. The benefit totaled $2.0 million and $2.2 million on an after-tax basis or $0.02 and $0.03 per diluted common share in 2008 and 2007, respectively.